• Neovasc (NVCN) has finalised the design of the Transfemoral Trans-Septal Tiara (TF/TS Tiara) system, for treatment of the heart condition called mitral valve disease.
  • The design freeze of the product now includes a modified, lower profile valve, and a steerable delivery system.
  • The TF/TS Tiara is designed to be minimally invasive, self-anchoring, trackable, and fully retrievable.
  • The company hopes to start a clinical study on the product’s feasibility in late 2020.
  • Neovasc’s share price is down 2.77 per cent, with shares currently trading at $3.51 apiece.

Specialty medical device company Neovasc (NVCN) has finalised the design for the Transfemoral Trans-Septal Tiara (TF/TS Tiara) system.

The Neovasc Tiara device is for treating a heart condition called mitral valve disease, or mitral regurgitation. 

The design freeze for the product includes a number of changes, including a modified, lower profile valve, and a steerable delivery system. These changes may expand the pool of potential patients who are eligible for treatment.

The TF/TS Tiara system’s final design is minimally invasive, self-anchoring, trackable, and fully retrievable. President and CEO of Neovasc, Fred Colen described the product as a potential “best-in-class system.”

The Tiara is currently under clinical investigation in the United States, Canada, Israel, and Europe. Neovasc expects that they will be able to start a clinical study on the product’s feasibility in late 2020.

Neovasc’s share price is down 2.77 per cent, with shares currently trading at $3.51 apiece at 2:43pm EST.

More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.